CERC - Cerecor Stock Trading

Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Mean reduction in LIGHT levels of approximately 80% compared to ...

ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into...

An initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candidates Financing provides flexibility and extends runway through multiple clinical catalysts expected in 2021 ROCKVILLE, Md. and ...